VBIO: Zikria Dean discloses securities transactions

By AlphaYouPublished Sep 24, 2026Form 4

Stocks in this disclosure

Reported activity

Zikria Dean

Reporting filer

Zikria Dean reported Grant or award in Valion Bio, Inc.: 50000 units of Restricted Stock Units (derivative), dated 2026-09-22. The full Form 4 contains 1 transaction entry.

Disclosed: Sep 24, 2026

Reported details

1 entry

All validated entries in this disclosure
Security	Owner	Date	Code	Action	Quantity	Price	Following holdings	Reporting delay	Filed terms and references
Restricted Stock Units (derivative)	Zikria Dean	2026-09-22	A	Grant or award	50000	0	50,000	2 days	Filed terms security Title: Restricted Stock Units id: F1 transaction Date: 2026-09-22 deemed Execution Date: transaction Form Type: 4 transaction Code: A equity Swap Involved: 0 transaction Timeliness: transaction Shares: 50000 transaction Price Per Share: 0 transaction Acquired Disposed Code: A id: F2 id: F2 underlying Security Title: Common Stock underlying Security Shares: 50000 shares Owned Following Transaction: 50000 id: F3 direct Or Indirect Ownership: D

Restricted Stock Units (derivative)

Owner: Zikria Dean
Date: 2026-09-22
Code: A
Action: Grant or award
Quantity: 50000
Price: 0
Following holdings: 50,000
Reporting delay: 2 days
Filed terms and references: Filed terms
security Title: Restricted Stock Units
id: F1
transaction Date: 2026-09-22
deemed Execution Date:
transaction Form Type: 4
transaction Code: A
equity Swap Involved: 0
transaction Timeliness:
transaction Shares: 50000
transaction Price Per Share: 0
transaction Acquired Disposed Code: A
id: F2
id: F2
underlying Security Title: Common Stock
underlying Security Shares: 50000
shares Owned Following Transaction: 50000
id: F3
direct Or Indirect Ownership: D

Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.
Zikria Dean: Interim CEO, Director.
F1: Each Restricted Stock Unit is convertible into one share of Common Stock.
F2: One fourth (1/4) of the Restricted Stock Units shall vest quarterly, with the first vesting occurring on December 22, 2026.
F3: These numbers have been adjusted to reflect the reverse stock split of the common stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026.

Original sources

SEC ownership filing

Prepared automatically from public filing data. Report a correction.

Security

Owner

Date

Code

Action

Quantity

Price

Following holdings

Reporting delay

Filed terms and references

Restricted Stock Units (derivative)

Zikria Dean

2026-09-22

Grant or award

50000

50,000

2 days

Filed terms

security Title: Restricted Stock Units
id: F1
transaction Date: 2026-09-22
deemed Execution Date:
transaction Form Type: 4
transaction Code: A
equity Swap Involved: 0
transaction Timeliness:
transaction Shares: 50000
transaction Price Per Share: 0
transaction Acquired Disposed Code: A
id: F2
id: F2
underlying Security Title: Common Stock
underlying Security Shares: 50000
shares Owned Following Transaction: 50000
id: F3
direct Or Indirect Ownership: D

Filing context

Quantities and prices are shown in the units filed. No trade value is inferred from their product.

Zikria Dean: Interim CEO, Director.

F1: Each Restricted Stock Unit is convertible into one share of Common Stock.

F2: One fourth (1/4) of the Restricted Stock Units shall vest quarterly, with the first vesting occurring on December 22, 2026.

F3: These numbers have been adjusted to reflect the reverse stock split of the common stock of Valion Bio, Inc., which underwent a reverse stock split at a ratio of 1-for-25 on August 31, 2026.